Brought to you by 
ZymoGenetics ends fusion protein patent case, grants rights
09 Dec 2008
Executive Summary
Biological products developer ZymoGenetics has dismissed its patent infringement case against Bristol-Myers Squibb and granted the Big Pharma global nonexclusive rights to its immunoglobin fusion protein patents.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ZymoGenetics ends fusion protein patent case, grants rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice